Literature DB >> 20952585

The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury.

Fei Qiao1, Carl Atkinson, Mark S Kindy, Anandakumar Shunmugavel, B Paul Morgan, Hongbin Song, Stephen Tomlinson.   

Abstract

Complement is implicated in the inflammatory response and the secondary neuronal damage that occurs after traumatic spinal cord injury (SCI). Complement can be activated by the classical, lectin, or alternative pathways, all of which share a common terminal pathway that culminates in formation of the cytolytic membrane attack complex (MAC). Here, we investigated the role of the alternative and terminal complement pathways in SCI. Mice deficient in the alternative pathway protein factor B (fB) were protected from traumatic SCI in terms of reduced tissue damage and demyelination, reduced inflammatory cell infiltrate, and improved functional recovery. In a clinically relevant paradigm, treatment of mice with an anti-fB mAb resulted in similarly improved outcomes. These improvements were associated with decreased C3 and fB deposition. On the other hand, deficiency of CD59, an inhibitor of the membrane attack complex, resulted in significantly increased injury and impaired functional recovery compared to wild-type mice. Increased injury in CD59-deficient mice was associated with increased MAC deposition, while levels of C3 and fB were unaffected. These data indicate key roles for the alternative and terminal complement pathways in the pathophysiology of SCI. Considering a previous study demonstrating an important role for the classical pathway in promoting SCI, it is likely that the alternative pathway plays a critical role in amplifying classical pathway initiated complement activation.

Entities:  

Mesh:

Year:  2010        PMID: 20952585      PMCID: PMC2993269          DOI: 10.2353/ajpath.2010.100158

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

Review 1.  Neuroinflammation in spinal cord injury: therapeutic targets for neuroprotection and regeneration.

Authors:  Jessica K Alexander; Phillip G Popovich
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

2.  Forelimb motor performance following dorsal column, dorsolateral funiculi, or ventrolateral funiculi lesions of the cervical spinal cord in the rat.

Authors:  G W Schrimsher; P J Reier
Journal:  Exp Neurol       Date:  1993-04       Impact factor: 5.330

3.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

4.  Absence of endogenous interleukin-10 enhances secondary inflammatory process after spinal cord compression injury in mice.

Authors:  Tiziana Genovese; Emanuela Esposito; Emanuela Mazzon; Rosanna Di Paola; Rocco Caminiti; Placido Bramanti; Alessandro Cappelani; Salvatore Cuzzocrea
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

Review 5.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

6.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

7.  A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.

Authors:  Yuxiang Huang; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration.

Authors:  Valeria Ramaglia; Rosalind Helen Mary King; Bryan Paul Morgan; Frank Baas
Journal:  Mol Immunol       Date:  2009-02-26       Impact factor: 4.407

9.  Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice.

Authors:  Philip F Stahel; Michael A Flierl; B Paul Morgan; Ivonne Persigehl; Christiane Stoll; Claudia Conrad; Basel M Touban; Wade R Smith; Kathryn Beauchamp; Oliver I Schmidt; Wolfgang Ertel; Iris Leinhase
Journal:  J Neuroinflammation       Date:  2009-01-08       Impact factor: 8.322

10.  Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury.

Authors:  Hal X Nguyen; Manuel D Galvan; Aileen J Anderson
Journal:  J Neuroinflammation       Date:  2008-06-25       Impact factor: 8.322

View more
  27 in total

1.  Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the "holy grail".

Authors:  Philip F Stahel; Michael A Flierl
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

2.  Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy.

Authors:  Khashayar Afshari; Amir Dehdashtian; Nazgol-Sadat Haddadi; Arvin Haj-Mirzaian; Arad Iranmehr; Mohammad Ali Ebrahimi; Seyed Mohammad Tavangar; Hedyeh Faghir-Ghanesefat; Fatemeh Mohammadi; Nastaran Rahimi; Abbas Norouzi Javidan; Ahmad Reza Dehpour
Journal:  Spinal Cord       Date:  2018-06-29       Impact factor: 2.772

3.  Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo.

Authors:  Sheri L Peterson; Hal X Nguyen; Oscar A Mendez; Aileen J Anderson
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

4.  The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.

Authors:  Andrew Elvington; Carl Atkinson; Hong Zhu; Jin Yu; Kazue Takahashi; Gregory L Stahl; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

5.  New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.

Authors:  Gloriane Schnabolk; Mee Keong Beon; Stephen Tomlinson; Bärbel Rohrer
Journal:  J Ocul Pharmacol Ther       Date:  2017-03-23       Impact factor: 2.671

6.  Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.

Authors:  Faith H Brennan; Trisha Jogia; Ellen R Gillespie; Linda V Blomster; Xaria X Li; Bianca Nowlan; Gail M Williams; Esther Jacobson; Geoff W Osborne; Frederic A Meunier; Stephen M Taylor; Kate E Campbell; Kelli Pa MacDonald; Jean-Pierre Levesque; Trent M Woodruff; Marc J Ruitenberg
Journal:  JCI Insight       Date:  2019-05-02

7.  Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice.

Authors:  Q Guo; J Cheng; J Zhang; B Su; C Bian; S Lin; C Zhong
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 8.  Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors:  Natalie E Scholpa; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2017-09-21       Impact factor: 4.030

Review 9.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

10.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.